Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
- Initiated first-in-human study for ABS-101 with interim data expected in H2 2025
- ABS-201 showed promising NHP data with >90% bioavailability and potential for Q8W-Q12W dosing intervals
- Strong cash position of $134.0M, sufficient to fund operations into H1 2027
- Revenue increased 33% YoY to $1.2M in Q1 2025
- Expected to sign one or more partnerships, including with a Large Pharma company, in 2025
- Net loss increased to $26.3M from $22.0M year-over-year
- R&D expenses increased 34% to $16.4M compared to Q1 2024
- SG&A expenses rose to $9.5M from $8.7M in Q1 2024
Insights
Absci's transition to clinical stage with lead program ABS-101 and advancing pipeline show promising execution despite widening losses.
Absci's announcement marks a significant milestone in the company's evolution as it transitions from a preclinical to clinical-stage biotech with the initiation of its first-in-human trial for ABS-101, an anti-TL1A antibody. This advancement positions the company in the competitive inflammatory disease space where TL1A inhibitors have shown promising results in conditions like inflammatory bowel disease.
The company's pipeline is showing systematic progression with important catalysts ahead. The ABS-101 trial—with interim data expected in H2 2025—features a standard Phase 1 design focusing on safety, tolerability, and pharmacokinetics in approximately 40 healthy volunteers. Meanwhile, the ABS-201 program targeting androgenetic alopecia is advancing with impressive preclinical data—showing extended half-life suggesting potential for infrequent dosing (Q8W-Q12W intervals) and high subcutaneous bioavailability (>90%) in non-human primates.
The hair loss market targeted by ABS-201 represents a substantial opportunity with 80 million potential patients in the U.S. alone, currently underserved by existing treatments. The preclinical data suggesting superior efficacy to minoxidil (current standard of care) could position ABS-201 favorably if translated to humans.
From a financial perspective, Absci reported $134.0 million in cash and equivalents, extending runway into first half of 2027. However, the quarterly net loss widened to $26.3 million from $22.0 million year-over-year, with R&D expenses increasing significantly to $16.4 million from $12.2 million, reflecting the costs of advancing multiple programs toward and into the clinic. Revenue remains minimal at $1.2 million, underscoring that Absci is still years away from potential product revenues.
The management's commentary on additional partnerships, including potential deals with Large Pharma, suggests the company continues to validate its platform technology while seeking to supplement its capital position and diversify risk through collaborations. These anticipated partnerships and the upcoming clinical readouts represent critical value-driving events that could significantly impact Absci's trajectory.
Absci shows pipeline progression but faces widening losses; cash runway into 2027 provides critical development flexibility.
Absci's Q1 results highlight a key transition as the company advances from technology platform to clinical-stage drug developer. While the top-line revenue remains minimal at $1.2 million (up from $0.9 million in Q1 2024), the real story lies in the pipeline progression and runway management.
The company reported a widening net loss of $26.3 million for Q1 2025 compared to $22.0 million in the same period last year, driven primarily by increased R&D spending ($16.4 million vs. $12.2 million). This 34% increase in R&D expenditure reflects the natural progression of multiple programs advancing toward and into clinical studies—a necessary investment phase for emerging biotechs.
Critically, Absci has successfully extended its cash position to $134.0 million as of March 31, 2025, up significantly from $112.4 million at year-end 2024. This provides a projected runway into the first half of 2027, covering multiple value-inflection points including the ABS-101 interim data in H2 2025 and potentially the ABS-201 interim efficacy readout in H2 2026.
The extended runway provides Absci with significant operational flexibility while reducing near-term financing pressure—a valuable position given the volatility in biotech capital markets. Management's indication of potential new partnerships, including with Large Pharma, suggests additional non-dilutive capital could further strengthen the balance sheet.
From a valuation perspective, Absci's progression from platform company to clinical-stage developer with multiple shots on goal represents a potential inflection point. The company now has a more traditional clinical-stage biotech profile with a lead asset in Phase 1 (ABS-101), a second asset approaching the clinic (ABS-201), and earlier-stage programs (ABS-301 and ABS-501) showing promising preclinical data.
The company's approach of combining wholly-owned assets with partnered and co-development programs provides a balanced risk profile. While revenue remains negligible for now, the anticipated partnerships could provide meaningful near-term cash inflows while the clinical programs progress toward potential value-driving data readouts over the next 18-24 months.
Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025
ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate extended half life and high subcutaneous bioavailability; anticipate Phase 1 initiation in early 2026
Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027
VANCOUVER, Wash. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the quarter ended March 31, 2025.
"The initiation of our first-in-human study of ABS-101 officially marks Absci’s transition to a clinical-stage biotech company, with ABS-201 also accelerating toward entering the clinic early next year," said Sean McClain, Founder and CEO. "As we continue to execute across our portfolio of wholly owned, partnered, and co-development programs, and with line of sight to additional new partnerships, I am excited for the pivotal updates we expect to share over the rest of this year, and beyond."
Recent Highlights
- Initiated dosing of participants in the first-in-human study of ABS-101, a potential best-in-class anti-TL1A antibody. Absci expects to report interim data from the ongoing study in the second half of 2025.
- Released NHP data for ABS-201 (anti-PRLR) androgenetic alopecia program, demonstrating:
- Extended half life with potential to translate into Q8W-Q12W dosing intervals in humans
- High subcutaneous bioavailability in NHPs at greater than
90% - Excellent manufacturability and developability profile to potentially enable future high concentration formulation of greater than 150mg/mL
Internal Pipeline Updates, Anticipated Program Progress, and 2025 Outlook
- ABS-101 (potential best-in-class anti-TL1A antibody): Today, Absci announced that it has initiated dosing of participants in the first-in-human study of ABS-101. The Phase 1 (ACTRN12625000212459p) randomized, double-blind, placebo-controlled, first-in-human study of single ascending doses of ABS-101 will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers. The study is expected to enroll approximately 40 healthy adult participants. The primary endpoint is safety and tolerability, with PK, PD, and immunogenicity serving as secondary endpoints. The Phase 1 interim data readout is expected in the second half of 2025.
- ABS-201 (potential best-in-class anti-PRLR antibody): ABS-201 is a potential best-in-class anti-PRLR antibody in development for androgenetic alopecia, an indication with significant unmet clinical need and a large potential patient population of approximately 80 million individuals in the U.S. alone. Absci has nominated a development candidate with a preclinical profile suggesting high affinity and potency, favorable safety and immunogenicity, extended half life for convenient infrequent dosing, and excellent developability and manufacturability. ABS-201 has the potential to offer a more efficacious and safe option as compared to current standard of care, evidenced by a preclinical model conducted for ABS-201 demonstrating improved hair regrowth compared to minoxidil. Absci also today released results from its NHP study for ABS-201, further supporting the program's potential to offer patients a convenient, durable, efficacious treatment option for androgenetic alopecia. Data from this study demonstrate extended half life and exhibit potential to translate into Q8W-Q12W dosing intervals in humans. The study also demonstrates high subcutaneous bioavailability of greater than
90% in NHPs, and the observed pharmacokinetic profile is projected to result in substantial exposure at target organs (specifically skin and hair follicles) at clinically relevant doses, which is expected to translate into meaningful clinical efficacy. Additionally, ABS-201's manufacturability and developability profile potentially enable a future high concentration formulation of greater than 150 mg/mL. Absci anticipates initiation of a Phase 1 clinical trial for ABS-201 in early 2026, with potential for an interim efficacy readout in the second half of 2026. - ABS-301 (potential first-in-class antibody for undisclosed immuno-oncology target): ABS-301 is a fully human antibody designed to bind to a novel target discovered through Absci's Reverse Immunology platform. Absci recently presented data for this program showing that expression of ABS-301’s target suggests broad potential in squamous cell carcinomas and beyond. For this program, Absci has optimized an antibody lead with high affinity and potency, and has successfully completed the first in vivo target validation study. The findings from the study demonstrate that signaling through the pathway drives a potent anti-tumor response, providing strong rationale for advancing into in vivo efficacy studies with ABS-301. These results support continued preclinical development and further exploration of ABS-301’s therapeutic potential.
- ABS-501 (potential best-in-class novel AI-designed anti-HER2 antibody): For this program, Absci has identified antibody leads using its zero-shot de novo AI technology with the following characteristics: novel epitope interactions, increased or equivalent affinity to trastuzumab in preclinical settings, efficacious against a trastuzumab-resistant xenograft tumor expressing wild-type HER2, and good developability.
- Drug Creation Partnerships: Absci continues to make further progress on its existing drug creation partnerships and anticipates signing one or more partnerships, including with a Large Pharma company, in 2025.
Absci continues to focus its investments and operations on advancing its internal pipeline of programs, alongside current and future partnered programs, while achieving ongoing platform improvements and operational efficiencies. Based on the company's current plans, Absci believes its existing cash, cash equivalents, and short-term investments will be sufficient to fund its operations into the first half of 2027.
First Quarter 2025 Financial Results
Revenue was
Research and development expenses were
Selling, general, and administrative expenses were
Net loss was
Cash, cash equivalents, and short-term investments as of March 31, 2025 were
Webcast Information
Absci will host a conference call to discuss its first quarter 2025 business updates and financial and operating results on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. A webcast of the conference call can be accessed at investors.absci.com. The webcast will be archived and available for replay for at least 90 days after the event.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics. These include ABS-101, a potentially best-in-class antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Forward-Looking Statements
Certain statements in this press release that are not historical facts are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements containing the words “will,” “pursues,” “anticipates,” “plans,” “believes,” “forecast,” “potential,” “goal,” “estimates,” “extends,” “expects,” and “intends,” or similar expressions. We intend these forward-looking statements, including statements regarding our expectations related to business operations, portfolio strategy, financial performance, and results of operations, our expectations and guidance related to the success of our partnerships, the gross use of cash, cash equivalents, and short-term investments, including revised guidance, our projected cash usage, needs, and runway, our expectations regarding the signing and number of additional partners and number of programs included in such partnerships, our technology development efforts and the application of those efforts, including for generalizing our platform, accelerating drug development timelines, improving the economics of drug discovery by lowering costs, and increasing the probability of success for drug development, our ability to execute with our partners to create differentiated antibody therapeutic candidates in an efficient manner, create and execute a successful development and commercialization strategy related to such candidates with current or future partners, and design and develop differentiated therapeutics to treat disease with unmet need, our ability to market our platform technologies to potential partners, and our internal asset programs, including our clinical development strategy, the progress and timing for various stages of development including advancement to lead stage, completion of pre-clinical studies, candidate selection, IND enabling studies, initiating clinical trials and the generation and disclosure of data related to these programs, the translation of preclinical results and data into product candidates, and the significance of preclinical results, including in comparison to competitor molecules and in leading to differentiated clinical efficacy or product profiles, to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, and we make this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. We can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved, and, furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, including, without limitation, risks and uncertainties relating to obtaining and maintaining necessary approvals from the FDA and other regulatory authorities, replicating in clinical trials promising or positive results observed in preclinical studies, our dependence on third parties to support our internal asset programs, including for the manufacture and supply of preclinical and clinical supplies of our product candidates or components thereof, our ability to effectively collaborate on research, drug discovery and development activities with our partners or potential partners, our existing and potential partners’ ability and willingness to pursue the development and commercialization of programs or product candidates under the terms of our partnership agreements, and overall market conditions and regulatory developments that may affect our and our partners’ activities under these agreements, along with those risks set forth in our most recent periodic report filed with the U.S. Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the U.S. Securities and Exchange Commission. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Contact:
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact:
press@absci.com
absci@methodcommunications.com
| Absci Corporation Unaudited Condensed Consolidated Statements of Operations | |||||||||
| For the Three Months Ended March 31, | |||||||||
| (In thousands, except for share and per share data) | 2025 | 2024 | |||||||
| Partner program revenue | $ | 1,179 | $ | 898 | |||||
| Operating expenses | |||||||||
| Research and development | 16,364 | 12,236 | |||||||
| Selling, general and administrative | 9,472 | 8,744 | |||||||
| Depreciation and amortization | 3,072 | 3,416 | |||||||
| Total operating expenses | 28,908 | 24,396 | |||||||
| Operating loss | (27,729 | ) | (23,498 | ) | |||||
| Other income (expense) | |||||||||
| Interest expense | (79 | ) | (176 | ) | |||||
| Other income, net | 1,458 | 1,711 | |||||||
| Total other income, net | 1,379 | 1,535 | |||||||
| Loss before income taxes | (26,350 | ) | (21,963 | ) | |||||
| Income tax benefit (expense) | 4 | (12 | ) | ||||||
| Net loss | $ | (26,346 | ) | $ | (21,975 | ) | |||
| Net loss per share: Basic and diluted | $ | (0.21 | ) | $ | (0.22 | ) | |||
| Weighted-average common shares outstanding: Basic and diluted | 124,461,439 | 99,393,333 | |||||||
| Absci Corporation Unaudited Condensed Consolidated Balance Sheets | |||||||||
| March 31, | December 31, | ||||||||
| (In thousands, except for share and per share data) | 2025 | 2024 | |||||||
| ASSETS | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 46,995 | $ | 41,213 | |||||
| Restricted cash | 16,076 | 15,947 | |||||||
| Short-term investments | 86,988 | 71,212 | |||||||
| Accounts receivable, net | 1,384 | — | |||||||
| Prepaid expenses and other current assets | 4,535 | 5,459 | |||||||
| Total current assets | 155,978 | 133,831 | |||||||
| Operating lease right-of-use assets | 3,716 | 3,968 | |||||||
| Property and equipment, net | 27,027 | 29,167 | |||||||
| Intangibles, net | 44,041 | 44,883 | |||||||
| Restricted cash, long-term | 1,054 | 1,054 | |||||||
| Other long-term assets | 631 | 705 | |||||||
| TOTAL ASSETS | $ | 232,447 | $ | 213,608 | |||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 4,947 | $ | 3,529 | |||||
| Accrued expenses | 4,256 | 6,842 | |||||||
| Contingent consideration | 12,750 | 12,750 | |||||||
| Long-term debt | 2,544 | 2,733 | |||||||
| Operating lease obligations | 1,656 | 1,608 | |||||||
| Financing lease obligations | 32 | 78 | |||||||
| Deferred revenue | 1,096 | 1,116 | |||||||
| Total current liabilities | 27,281 | 28,656 | |||||||
| Long-term debt, net of current portion | 682 | 1,257 | |||||||
| Operating lease obligations, net of current portion | 4,003 | 4,429 | |||||||
| Other long-term liabilities | 1,685 | 133 | |||||||
| TOTAL LIABILITIES | 33,651 | 34,475 | |||||||
| STOCKHOLDERS' EQUITY | |||||||||
| Preferred stock | — | — | |||||||
| Common stock | 13 | 12 | |||||||
| Additional paid-in capital | 734,711 | 688,726 | |||||||
| Accumulated deficit | (535,947 | ) | (509,601 | ) | |||||
| Accumulated other comprehensive income (loss) | 19 | (4 | ) | ||||||
| TOTAL STOCKHOLDERS' EQUITY | 198,796 | 179,133 | |||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 232,447 | $ | 213,608 | |||||
FAQ
What were Absci's (ABSI) key financial results for Q1 2025?
What is the status of Absci's (ABSI) ABS-101 clinical trial?
What were the key findings from Absci's (ABSI) ABS-201 non-human primate study?
How long can Absci (ABSI) fund its operations with current cash?
When does Absci (ABSI) expect to begin Phase 1 trials for ABS-201?
